FDMT Total Stockholder Equity vs Total Current Liabilities Analysis

FDMT Stock  USD 4.88  0.16  3.39%   
4D Molecular financial indicator trend analysis is way more than just evaluating 4D Molecular Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether 4D Molecular Therapeutics is a good investment. Please check the relationship between 4D Molecular Total Stockholder Equity and its Total Current Liabilities accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 4D Molecular Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

Total Stockholder Equity vs Total Current Liabilities

Total Stockholder Equity vs Total Current Liabilities Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of 4D Molecular Therapeutics Total Stockholder Equity account and Total Current Liabilities. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between 4D Molecular's Total Stockholder Equity and Total Current Liabilities is 0.45. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Total Current Liabilities in the same time period over historical financial statements of 4D Molecular Therapeutics, assuming nothing else is changed. The correlation between historical values of 4D Molecular's Total Stockholder Equity and Total Current Liabilities is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of 4D Molecular Therapeutics are associated (or correlated) with its Total Current Liabilities. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Current Liabilities has no effect on the direction of Total Stockholder Equity i.e., 4D Molecular's Total Stockholder Equity and Total Current Liabilities go up and down completely randomly.

Correlation Coefficient

0.45
Relationship DirectionPositive 
Relationship StrengthWeak

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Total Current Liabilities

Total Current Liabilities is an item on 4D Molecular balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of 4D Molecular Therapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.
Most indicators from 4D Molecular's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into 4D Molecular Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in 4D Molecular Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Sales General And Administrative To Revenue is likely to gain to 2.07 in 2025, whereas Selling General Administrative is likely to drop slightly above 21.7 M in 2025.
 2022 2023 2024 2025 (projected)
Interest Income2.6M9.2M10.5M11.1M
Net Interest Income2.6M9.2M10.5M11.1M

4D Molecular fundamental ratios Correlations

0.960.960.39-0.910.950.85-0.65-0.96-0.890.940.990.85-0.390.881.00.320.980.9-0.530.990.860.320.940.841.0
0.960.990.5-0.880.860.82-0.64-0.88-0.90.910.920.83-0.260.930.950.360.930.97-0.430.960.850.220.890.830.95
0.960.990.45-0.90.870.83-0.61-0.9-0.90.920.930.84-0.240.950.950.440.940.96-0.40.970.840.210.890.830.95
0.390.50.45-0.30.380.31-0.33-0.35-0.480.190.350.370.330.330.40.350.360.46-0.330.410.48-0.380.50.380.41
-0.91-0.88-0.9-0.3-0.87-0.950.80.870.95-0.94-0.88-0.950.31-0.91-0.89-0.27-0.87-0.870.37-0.87-0.94-0.29-0.89-0.95-0.89
0.950.860.870.38-0.870.87-0.67-0.96-0.870.880.960.87-0.420.760.950.210.950.8-0.690.950.870.310.990.850.95
0.850.820.830.31-0.950.87-0.92-0.79-0.960.90.81.0-0.270.840.820.040.840.86-0.560.810.980.20.91.00.82
-0.65-0.64-0.61-0.330.8-0.67-0.920.540.87-0.71-0.57-0.920.11-0.68-0.610.19-0.64-0.710.58-0.59-0.92-0.02-0.75-0.93-0.61
-0.96-0.88-0.9-0.350.87-0.96-0.790.540.82-0.89-0.98-0.790.45-0.78-0.97-0.38-0.94-0.780.51-0.96-0.79-0.39-0.94-0.77-0.97
-0.89-0.9-0.9-0.480.95-0.87-0.960.870.82-0.87-0.83-0.960.12-0.91-0.86-0.23-0.88-0.930.54-0.87-0.97-0.05-0.92-0.97-0.87
0.940.910.920.19-0.940.880.9-0.71-0.89-0.870.920.89-0.530.870.930.140.910.88-0.420.910.870.490.880.880.93
0.990.920.930.35-0.880.960.8-0.57-0.98-0.830.920.8-0.440.831.00.350.970.84-0.520.990.810.380.940.790.99
0.850.830.840.37-0.950.871.0-0.92-0.79-0.960.890.8-0.270.830.830.040.830.86-0.560.810.990.20.911.00.82
-0.39-0.26-0.240.330.31-0.42-0.270.110.450.12-0.53-0.44-0.27-0.08-0.40.37-0.32-0.130.18-0.34-0.22-0.97-0.33-0.22-0.39
0.880.930.950.33-0.910.760.84-0.68-0.78-0.910.870.830.83-0.080.860.460.870.95-0.270.870.820.080.790.840.86
1.00.950.950.4-0.890.950.82-0.61-0.97-0.860.931.00.83-0.40.860.340.980.88-0.520.990.830.330.940.811.0
0.320.360.440.35-0.270.210.040.19-0.38-0.230.140.350.040.370.460.340.30.310.280.380.07-0.270.210.050.35
0.980.930.940.36-0.870.950.84-0.64-0.94-0.880.910.970.83-0.320.870.980.30.9-0.630.990.830.230.940.820.98
0.90.970.960.46-0.870.80.86-0.71-0.78-0.930.880.840.86-0.130.950.880.310.9-0.450.90.870.080.840.860.88
-0.53-0.43-0.4-0.330.37-0.69-0.560.580.510.54-0.42-0.52-0.560.18-0.27-0.520.28-0.63-0.45-0.55-0.580.04-0.68-0.56-0.52
0.990.960.970.41-0.870.950.81-0.59-0.96-0.870.910.990.81-0.340.870.990.380.990.9-0.550.820.270.940.80.99
0.860.850.840.48-0.940.870.98-0.92-0.79-0.970.870.810.99-0.220.820.830.070.830.87-0.580.820.140.930.990.83
0.320.220.21-0.38-0.290.310.2-0.02-0.39-0.050.490.380.2-0.970.080.33-0.270.230.080.040.270.140.230.150.32
0.940.890.890.5-0.890.990.9-0.75-0.94-0.920.880.940.91-0.330.790.940.210.940.84-0.680.940.930.230.90.94
0.840.830.830.38-0.950.851.0-0.93-0.77-0.970.880.791.0-0.220.840.810.050.820.86-0.560.80.990.150.90.81
1.00.950.950.41-0.890.950.82-0.61-0.97-0.870.930.990.82-0.390.861.00.350.980.88-0.520.990.830.320.940.81
Click cells to compare fundamentals

4D Molecular Account Relationship Matchups

4D Molecular fundamental ratios Accounts

202020212022202320242025 (projected)
Total Assets288.3M353.5M261.8M339.9M390.9M224.1M
Other Current Liab8.4M9.0M6.7M12.0M13.8M7.0M
Total Current Liabilities16.7M16.3M15.7M19.0M21.8M14.9M
Total Stockholder Equity256.4M(207.0M)(314.5M)307.8M354.0M371.7M
Other Liab15.3M15.2M2.8M1.3M1.2M1.1M
Net Tangible Assets(73.0M)256.4M319.1M231.3M266.0M279.3M
Property Plant And Equipment Net5.1M29.0M35.3M31.7M36.4M38.2M
Current Deferred Revenue6.6M2.6M884K273K245.7K233.4K
Net Debt(276.7M)(299.0M)(202.5M)(234.4M)(211.0M)(221.5M)
Retained Earnings(135.7M)(207.0M)(314.5M)(415.3M)(373.8M)(355.1M)
Accounts Payable1.8M4.8M3.3M3.5M4.0M2.6M
Cash276.7M315.4M218.6M249.1M286.5M192.5M
Non Current Assets Total5.7M38.1M41.3M43.3M49.8M52.3M
Non Currrent Assets Other602K(58.5M)1.1M684K615.6K646.4K
Other Assets429K677K602K1.1M1.2M640.8K
Cash And Short Term Investments276.7M315.4M218.6M288.2M331.5M198.7M
Net Receivables978K1.5M47K700K630K620.8K
Common Stock Shares Outstanding26.7M27.7M32.4M39.1M45.0M28.2M
Liabilities And Stockholders Equity288.3M353.5M(284.0M)339.9M390.9M410.4M
Non Current Liabilities Total15.2M18.0M14.8M13.1M11.8M11.2M
Other Current Assets8.9M8.5M7.0M8.4M9.6M5.7M
Other Stockholder Equity103.7M526.5M547.0M723.1M831.6M873.2M
Total Liab31.9M560.5M30.5M32.1M36.9M35.0M
Net Invested Capital256.4M319.1M231.3M307.8M354.0M371.7M
Property Plant And Equipment Gross5.1M34.3M43.1M43.6M50.1M52.6M
Total Current Assets282.7M315.4M220.5M296.6M341.1M202.1M
Accumulated Other Comprehensive Income(288.3M)(423K)(1.2M)16K18.4K19.3K
Non Current Liabilities Other1.9M17.8M14.6M248K285.2K270.9K
Net Working Capital265.9M239.9M204.8M277.6M319.3M178.0M
Property Plant Equipment5.0M5.1M29.0M22.3M25.6M26.9M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for FDMT Stock Analysis

When running 4D Molecular's price analysis, check to measure 4D Molecular's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4D Molecular is operating at the current time. Most of 4D Molecular's value examination focuses on studying past and present price action to predict the probability of 4D Molecular's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4D Molecular's price. Additionally, you may evaluate how the addition of 4D Molecular to your portfolios can decrease your overall portfolio volatility.